Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-041 add-on crossover study for motivational anhedonia in stable schizophrenia
2017-001084-20Phase 2Terminated
- Sponsor
- Takeda
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zelatriazin in schizophrenia, sponsored by Takeda. Started Jun 2017; status: terminated.
02
Drugs
zelatriazin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-001084-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001084-20.